Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated (18)F–Fluorodeoxyglucose ((18)F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

BACKGROUND: Tyrosine kinase inhibitors are the first line standard of care for treatment of metastatic renal cell carcinoma (RCC). Accurate response assessment in the setting of antiangiogenic therapies remains suboptimal as standard size-related response criteria do not necessarily accurately refle...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly-Morland, Christian, Rudman, Sarah, Nathan, Paul, Mallett, Susan, Montana, Giovanni, Cook, Gary, Goh, Vicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455133/
https://www.ncbi.nlm.nih.gov/pubmed/28578690
http://dx.doi.org/10.1186/s12885-017-3371-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455133/
https://www.ncbi.nlm.nih.gov/pubmed/28578690
http://dx.doi.org/10.1186/s12885-017-3371-9

Ejemplares similares